Imaging Assessments of ARPKD Kidney Disease Progression
NCT07201025
This study is recruiting at 2 US sites in 2 states, according to its ClinicalTrials.gov record last updated .
Summary
Autosomal Recessive Polycystic Kidney Disease (ARPKD) is a potentially lethal genetic disorder for which there are currently no disease specific treatments. Clinical trials have been limited by the absence of robust measures of disease progression.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Autosomal Recessive Polycystic Kidney Disease
Eligibility basics and study details
- Study type
- Observational
- Phase
- Not applicable
- Ages
- 6 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- The Cleveland Clinic
- Last updated on ClinicalTrials.gov
- November 21, 2025
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Ohio · 1
- Cleveland Clinic · Cleveland, OH
Pennsylvania · 1
- Children's Hospital of Philadelphia · Philadelphia, PA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.